{"id":23941,"date":"2025-12-23T22:58:50","date_gmt":"2025-12-23T17:28:50","guid":{"rendered":"http:\/\/43.205.138.160\/?post_type=article&p=23941"},"modified":"2025-12-23T22:58:50","modified_gmt":"2025-12-23T17:28:50","slug":"star-%e0%a4%ab%e0%a4%be%e0%a4%b0%e0%a5%8d%e0%a4%ae%e0%a4%be-%e0%a4%95%e0%a5%80-%e0%a4%a8%e0%a4%88-%e0%a4%89%e0%a4%a1%e0%a4%bc%e0%a4%be%e0%a4%a8-%e0%a4%ae%e0%a5%81%e0%a4%a8%e0%a4%be","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/star-%e0%a4%ab%e0%a4%be%e0%a4%b0%e0%a5%8d%e0%a4%ae%e0%a4%be-%e0%a4%95%e0%a5%80-%e0%a4%a8%e0%a4%88-%e0%a4%89%e0%a4%a1%e0%a4%bc%e0%a4%be%e0%a4%a8-%e0%a4%ae%e0%a5%81%e0%a4%a8%e0%a4%be\/","title":{"rendered":"\u201cSTAR \u2013 \u092b\u093e\u0930\u094d\u092e\u093e \u0915\u0940 \u0928\u0908 \u0909\u0921\u093c\u093e\u0928, \u092e\u0941\u0928\u093e\u092b\u093c\u0947 \u0915\u093e \u092c\u0922\u093c\u0924\u093e \u0938\u092b\u093c\u0930 \u2013 \u092f\u0942\u090f\u0938 \u091c\u0947\u0928\u0947\u0930\u093f\u0915\u094d\u0938 \u0915\u093e \u0930\u093e\u091c\u093e!\u201d"},"content":{"rendered":"

Strides Pharma Science Ltd (STAR) – Complete Analysis Report:
\n<\/strong>Strides Pharma Science Ltd (STAR) trades at \u20b9942 with 3-day buying pressure from supports at \u20b9880-900, driven by Q2FY26 profit surge +84% and US growth outlook. Rally shows momentum but faces resistance; watch key levels for continuation amid pharma sector rotation.<\/p>\n

\u200bTechnical Analysis:
\n<\/strong>Pivot at \u20b9851 with supports \u20b9828\/\u20b9811\/\u20b9788; resistance \u20b9868\/\u20b9891\/\u20b9908. RSI neutral post-consolidation breakout, volume uptick confirms buying; above 50-day EMA \u20b9900 signals short-term bullish bias. 1-week +1.14%, 1-month -1.19% but 1-year +36% supports accumulation.<\/p>\n

\u200bFundamental Analysis:
\n<\/strong>Market cap \u20b98,684 Cr, P\/E 20.0 (peer median 30.85), ROE 151% (3-yr 50.4%), ROCE 14.7%, dividend yield 0.42%. Q2 revenue \u20b91,221 Cr (+4.6% YoY), EBITDA +25.4%, PAT +84% operational; 5-yr profit CAGR 124% but sales growth lags at 10.6%.<\/p>\n

\u200bRecent Buying Pressure Reasons:
\n<\/strong>3-day buying follows Q2 earnings beat (PAT +84% YoY) and $400M US FY28 target guidance; analysts target \u20b91,220 amid niche generics momentum. Reduced debt + improving liquidity attracts value hunters post-consolidation.<\/p>\n

\u200bRally Continuation & Key Levels:
\n<\/strong>Rally likely continues to \u20b9975-1,000 if holds \u20b9880 support; breakdown below \u20b9811 risks pullback to \u20b9787. Target \u20b91,220 on sustained volume; monitor Nov 21 Kotak conference for catalysts. Bullish if breaks \u20b9908 decisively.<\/p>\n

\u200bPositive News & Events Impact:
\n<\/strong>Q2FY26 Earnings (Nov 5): Revenue +4.6%, EBITDA +25.4%, US\/emerging markets growth focus; $400M US target FY28.\u200b
\nUSFDA Approvals: Recent nods for anti-bacterial capsules, EIR for US facility boost regulated market credibility.\u200b
\nManagement Change (Dec 3): New EVP-HR strengthens leadership amid expansion.\u200b
\nImpact: Enhances export outlook (100+ countries), niche softgels leadership; Piotroski F-score 7 signals improving health.<\/p>\n

\u200bPositive Points:
\n<\/strong>Profit turnaround: 5-yr CAGR 124%, ROE 151% last year.
\nDebt reduction, EBITDA margins 19%, global generics presence (US\/EU\/Australia).
\nStrong quarterly growth, niche formulations edge.<\/p>\n

\u200bNegative Points:
\n<\/strong>Poor 5-yr sales growth 10.6%, promoter holding low 27.9% (44.1% pledged).
\nTrading at 3.19x book value \u20b9299, management score poor.
\nWorking capital days improved but inventory high 236 days.<\/p>\n

Disclaimer & Disclosure:
\n<\/strong>Investogainer Research (SEBI Reg INH000012856) provides educational analysis only. No buy\/sell recommendations. Past performance no guarantee of future results. Consult certified advisor. No personal holdings in STAR. Risks include forex volatility, regulatory delays.<\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[388,386,400,130,121,186,169,129,127,155],"class_list":["post-23941","article","type-article","status-publish","hentry","article-category-learn","article-tags-calloptions","article-tags-optionstrading","article-tags-technicalanalysis","article-tags-expert-analysis","article-tags-investment-opportunities","article-tags-investmenteducation","article-tags-investmentstrategy","article-tags-stock-market-tips","article-tags-successful-investing","article-tags-wealthbuilding"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/23941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=23941"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=23941"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=23941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}